Our previous series of studies have proven that olfactory ensheathing cell (OEC) transplantation appears to be able to slow the rate of clinical progression after OEC transplantation in the first 4 months and cell intracranial (key points for neural network restoration, KPNNR) and/or intraspinal (impaired segments) implants provide benefit for patients (including both the bulbar onset and limb onset subtypes) with amyotrophic lateral sclerosis (ALS). Here we report the results of cell therapy in patients with ALS on the basis of long-term observation following multiple transplants. From March of 2003 to January of 2010, 507 ALS patients received our cellular treatment. Among them, 42 patients underwent further OEC therapy by the route of KPNNR for two or more times (two times in 35 patients, three times in 5 patients, four times in 1 patient, and five times in 1 patient). The time intervals are 13.1 (6-60) months between the first therapy and the second one, 15.2 (8-24) months between the second therapy and the third one, 16 (6-26) months between the third therapy and the fourth one, and 9 months between the fourth therapy and the fifth time. All of the patients exhibited partial neurological functional recovery after each cell-based administration. Firstly, the scores of the ALS Functional Rating Scale (ALS-FRS) and ALS Norris Scale increased by 2.6 + 2.4 (0-8) and 4.9 + 5.2 (0-20) after the first treatment, 1.1 + 1.3 (0-5) and 2.3 + 2.9 (0-13) after the second treatment, 1.1 + 1.5 (0-4), and 3.4 + 6.9 (0-19) after the third treatment, 0.0 + 0.0 (0-0), and 2.5 + 3.5 (0-5) after the fourth treatment, and 1 point after the fifth cellular therapy, which were evaluated by independent neurologists. Secondly, the majority of patients have achieved improvement in electromyogram (EMG) assessments after the first, second, third, and fourth cell transplantation. After the first treatment, among the 42 patients, 36 (85.7%) patients' EMG test results improved, the remaining 6 (14.3%) patients' EMG results showed no remarkable change. After the second treatment, of the 42 patients, 30 (71.4%) patients' EMG results improved, 11 (26.2%) patients showed no remarkable change, and 1 (2.4%) patient became worse. After the third treatment, out of the 7 patients, 4 (57.1%) patients improved, while the remaining 3 (42.9%) patients showed no change. Thirdly, the patients have partially recovered their breathing ability as demonstrated by pulmonary functional tests. After the first treatment, 20 (47.6%) patients' pulmonary function ameliorated. After the second treatment, 18 (42.9%) patients' pulmonary function improved. After the third treatment, 2 (28.6%) patients recovered some pulmonary function. After the fourth and fifth treatment, patients' pulmonary function did not reveal significant change. The results show that multiple doses of cellular therapy definitely serve as a positive role in the treatment of ALS. This repeated and periodic cellbased therapy is strongly recommended for the patients, for better controlling this progressive deterioration disorder.
INTRODUCTION
Death due to respiratory failure occurs typically 2-5 years after disease onset (84) . Although the etiology of ALS remains largely unknown, the pathological findings Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, neurodegenerative disease caused by the degenera-are commonly the degeneration of the corticospinal tracts associated with loss of upper and/or lower motor tion of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement.
neurons and demyelinated axons. The corticospinal tract degeneration is most evident in the lower parts of the the patients had neurological functional improvements and/or delayed the deterioration following the first cell spinal cord, but it can be traced up through the brain stem to the posterior limb of the internal capsule and therapy; however, they usually need to receive further cell medicine for maintaining the improved outcome. In corona radiata by means of fat stains, which show the macrophages that accumulate in response to myelin this article, we report the effects of multiple cell therapies on neurological function, electromyogram, and pul-degeneration (74) . The food and drug administration (FDA) of the US has approved only one drug treatment monary function in patients suffered with ALS on basis of the long-term observation. for the disease, Riluzole, which is believed to reduce damage to motor neurons by decreasing the release of MATERIALS AND METHODS glutamate via activation of glutamate transporters. Cur-Patients rently, no treatments can cure ALS. Cell-based therapy had been introduced clinically as a promising attempt to Patients with a "probable" or "definite" ALS diagnosis (according to the revised El Escorial criteria) (9) treat ALS and prolong the life span during the last 20 years through the potential neuroprotective effect, neur-were eligible for inclusion in the study. Between March of 2003 and January of 2010, a total of 507 ALS patients orestoration, and neuroplasticity, etc. (2, 10, 13, 14, 19, 22, (33) (34) (35) 37, (61) (62) (63) . Olfactory ensheathing cells (OECs) underwent our cellular treatment. Of them, 42 patients (31 males and 11 females) underwent further OEC ther-are a novel glia that displays Schwann cells together with astrocyte-like properties. They are a source of apy by the route of KPNNR for two or more times (two times in 35 patients, three times in 5 patients, four times growth factors and adhesion molecules that have a very important role as neuronal support enhancing cellular in 1 patient, and five times in 1 patient). Their ages ranged from 20 to 73 with an average of 49.9 ± 10.7 survival (48,67).
Our previous studies have implied that OEC intra-years. The duration before the first cell transplantation varied from 0.5 to 8.0 (mean 2.9 ± 2.0) years. In this cranial (key points for neural network restoration, KPNNR) and/or intraspinal transplantation are indeed study, upper limb onset occurred in 22, lower limb onset in 11, bulb onset in 7, upper and lower limb onset in 1, beneficial for patients with ALS (12, 34, 35) . Our further study has suggested that OEC transplantation is capable and neck onset in 1. The time intervals were 6-60 (mean 12.1 ± 8.9) months between the first therapy and the sec-of slowing the rate of clinical progression within the initial 4 months after transplantation (34) . The majority of ond one, 8-24 (mean 15.0 ± 5.7) months between the There was a statistically significant difference between pretreatment ALS-FRS and Norris scale score and posttreatment score after the first and second doses of cell therapy (p < 0.01). Increased scores of ALS-FRS in first group was significantly more than the other three groups (p < 0.05) and no statistic differences were shown between second and third, third and fourth groups (p > 0.05), but it is difference between second and fourth groups (p < 0.05). There was statistic difference on increased score of Norris scale between first and second cell transplant (p = 0.019).
second therapy and the third one, 6-26 (mean 16.0 ± OEC Harvest 14.1) months between the third therapy and the fourth one, and 9 months between the fourth therapy and the OECs were isolated and cultured in GMP standard laboratory as described previously (55) . In brief, OECs fifth one. The study was conducted at Beijing Hongtianji Neuroscience Academy in conjunction with Beijing were isolated from aborted human fetal olfactory bulb with donor consent. The OECs were cultured and propa-Rehabilitation Center in accordance with guidelines issued by the Chinese Ministry of Health (91-006) (69). gated for 2-3 weeks and characterized by immunostaining with antibodies against p75 (a neurotrophin receptor All eligible patients and/or families were fully informed about the nature of the study, and provided written that is specific for OECs, Sigma) (55) . OECs from one to two fetuses, which represent 2 × 10 6 cells/100 µl, informed consent to participate in the study. . At 2 weeks (C, D) and 6 months (E, F) after the first cell treatment, EMG showed the recruitment of the maximal voluntary contraction of both sides of first dorsal interosseous (Int) muscles was changed, and its pattern was improved and more intensive. Following the third operation, recruitment of maximal voluntary contraction increased in the vastus medialis (Med) muscles bilaterally, and the pattern was more intensive (G, H). After the fourth cell transplantation, the motor unit potentials were recorded in the left vastus med muscle. The recruitment of maximal voluntary contraction was improved and more intensive in the right vastus med muscle (I, J). This patient's medical status keeps very well during the 5 years after four cell transplantations (K, red arrows show the cell transplantation and blue arrow shows the attack of lacunar infarction). were transplanted for each patient. In accordance with recorded successfully which failed to occur preoperatively. We performed pulmonary function by using pulmo-the Chinese Pharmacopoeia procedure, the bacteria, viruses, fungi, mycoplasma, and endotoxin testing were nary function analyzer (CHEST HI-801, Japan). We tested vital capacity (VC), forced vital capacity (FVC), done. Cell quality indicators: cell activity ≥85%. Human leukocyte antigen-DR (HLA-DR)-matching tests were forced expiratory volume (FEV1), FEV1/FVC, maximum minute ventilation (MVV), maximal expiratory carried out before transplantation to ensure the histocompability between the donors and the recipients. pressure (MEP), and maximum inspiratory pressure (MIP) pre-and post-cell transplantation (2-4 weeks OEC Surgical Transplantation after operation). Initially, 1 × 10 6 cells/50 µl were transplanted into the involved spinal cord under general anesthesia. Then
Statistical Analysis the cell transplantation procedure consisted of the injec-
The data were expressed as means ± SD. The data tion of 2 × 10 6 cells/100 µl into KPNNR within the were analyzed with SPSS for Windows (version 13.0; corona radiata of the frontal lobes bilaterally using ste-SPSS, Inc., Chicago, IL), for either two-tailed paired reotactic techniques under local anesthesia (11) as T2 samples t-test, or one-way ANOVA test (Bonferroni valweighted and, especially, fluid attenuated inversion ues for equal variances, but Tamhane's T2 values for no recovery (FLAIR) MR images show signal pathological homogeneity of variances). A significance level of 0.05 changes that reflect Wallerian changes in the corticospiwas used. nal tracts ( Fig. 1 ).
RESULTS

Clinical Evaluation (Including Neurological Function, Neurological Function MRI, EMG, and Pulmonary Function)
The neurological function of patients was evaluated All of the patients had neurological functional recovery after multiple cell-based administrations. After the by three neurologists independently before and at 2-4 weeks after cell intracranial transplant. The ALS Func-first treatment, the scores of ALS-FRS increased from 24.5 ± 7.1 to 27.1 ± 7.1 (t = −7.084, p < 0.001) and ALS tional Rating Scale (ALS-FRS) and the Modified Norris bulbar and Limb scale (23), together with a detailed Norris Scale increased from 55.9 ± 20.9 to 60.8 ± 22.1 (t = −6.148, p < 0.001); after the second treatment, ALS-video record of each patient were taken.
A magnetic resonance imaging (MRI) scan was done FRS score increased from 20.1 ± 7.3 to 21.1 ± 7.4 (t = −5.200, p < 0.001) and Norris score increased from 43.0 ± before each cellular surgery. Electromyogram (EMG) and pulmonary function test were performed pre-and 21.6 to 45.6 ± 21.8 (t = −5.003, p < 0.001); after the third treatment, ALS-FRS score increased from 18.3 ± post-cell transplantation (2-4 weeks after operation).
We used Keypoint-4 electromyograph of evoked poten-7.7 to 19.4 ± 8.4 (t = −2.066, p = 0.084) and Norris score increased from 36.1 ± 20.9 to 39.6 ± 23.1 (t = tial instrument from Denmark. In EMG, 8-12 muscles were tested, which included proximal and distal part of −1.310, p = 0.238); after the fourth treatment, ALS-FRS score had no change with 20.5 ± 4.9 and Norris score four limbs, muscles of tongue, and sternocleidomastoideus muscle. The amount of motor unit potentials (MUPs), increased from 37.5 ± 24.7 to 40.0 ± 28.3 (t = −1.000, p = 0.500). The scores of ALS-FRS and ALS Norris wave amplitude, and persistent discharge ability were recorded during maximal voluntary contraction of tested Scale increased by 2.6 ± 2.4 (0-8) and 4.9 ± 5.2 (0-20) after the first treatment, 1.1 ± 1.3 (0-5) and 2.3 ± 2.9 muscle. The results described as follows mean EMG improvements: spontaneous potentials diminished, recruit-(0-13) after the second treatment, 1.1 ± 1.5 (0-4) and 3.4 ± 6.9 (0-19) after the third treatment, 0.0 ± 0.0 ment pattern of the maximal voluntary contraction of involved muscles became more intensive and partially (0-0) and 2.5 ± 3.5 (0-5) after the fourth treatment, and 1 point after the fifth cellular therapy (Table 1, Fig. 2 ). together with an increased number of MUPs, and MUPs No patients in this study experienced side effects or increased number of motor unit potential in 28 patients (66.7%); c) motor unit potential recorded successfully, complications following the operation. Re-MRI studies did not show any development of tumors, hemorrhages, which failed to occur before surgery in 2 patients (4.8%).
After the third treatment, among the 7 patients, 4 edema, cyst formations, infections, disruption of neural structures, and other pathological findings in the trans-(57.1%) patients' EMG results improved, 3 (42.9%) patients no change. Improvements of electromyogram planted sites.
includes: a) spontaneous potentials diminished in 1 Electromyogram (EMG) Study patient (14.3%); b) recruitment pattern of the maximal voluntary contraction of involved muscles improved, After the first treatment, among the total of 42 patients, 36 (85.7%) patients' EMG results become bet-which became more intensive and partially together with increased number of motor unit potential in 2 patients ter and the remaining 6 (14.3%) patients showed no remarkable change. Improvements of EMG include: (28.6%) (Fig. 2) ; c) motor unit potential recorded successfully, which failed to occur before surgery in 1 a) spontaneous potentials diminished in 10 patients (23.8%); b) recruitment pattern of the maximal volun-patient (14.3%). Two patients received the fourth treatment, and both tary contraction of involved muscles improved, which became more intensive and partially together with EMG results ameliorated. The improvements were both in the recruitment pattern of the maximal voluntary con-increased number of motor unit potential in 33 patients (78.6%); c) motor unit potential recorded successfully, traction of involved muscles (Fig. 3) . One patient received the fifth treatment and the EMG which failed to occur before surgery in 3 patients (7.1%).
After the second treatment, out of the 42 patients, results improved. The improvement was successful recording of motor unit potential. 30 (71.4%) had improvement, 11 (26.2%) showed no remarkable change, and 1 (2.4%) worsen. Improvements
Pulmonary Function of EMG include: a) spontaneous potentials diminished in 8 patients (19.0%); b) recruitment pattern of the maxi-
The First Treatment. Twenty-one patients' pulmonary function was normal. So we analyzed the other 21 mal voluntary contraction of involved muscles improved, which became more intensive and partially together with patients' pulmonary function. The details of the results were shown in Table 2 . There was no significant differ-variances, etc. Some of our patients obtained long-term control of the progression of ALS and improved their ence between pretreatment and posttreatment.
daily quality of life. The Second Treatment. Fifteen patients' pulmonary Given the potential risks following the traditional spifunction was normal. So we analyzed the other 27 nal cord surgery under general anesthesia in ALS patients' pulmonary function. The details of the results patients, Huang et al. first proposed the key point for were shown in Table 3 . No significant difference neural network restoration (KPNNR) in brain based on between pretreatment and posttreatment was found.
a set of successful cases in clinical practice (8, 35) . The The Third Treatment. We analyzed these 7 patients' core target where the cells should be transplanted into is pulmonary function. The details of the results were located anterior 1/4-1/3 of the lateral ventricle and shown in Table 4 . There was no significant difference 23-27 mm away from the midline. This site is where between pretreatment and posttreatment.
the frontal corona radiata pyramidal tract passes The Fourth and Fifth Treatments. Two patients through, and represents a point at which numerous proreceived the fourth treatment and 1 patient received the jection fibers, association fibers, and commissural fibers fifth treatment. After the fourth treatment, 1 patient converge. After being transplanted into this important became better and the other patient revealed no change.
"point" in the brain, the cells will initiate an extensive After the fifth treatment, the patient's pulmonary funcbidirectional remodeling in the entire neural network tion kept stable.
including the cerebrum, cerebellum, and spinal cord. Evidence shows that the procedure of KPNNR cell DISCUSSION transplantation under local anesthesia is safer and better tolerated, especially in ALS patients with impairment The pivotal practical therapeutic goal in neurodegenerative diseases is currently to diminish neural dysfunc-of breathing.
The olfactory system is unique in that it supports con-tion using varied strategies (1, 32, 41, 64, 77) . There have been accumulating basic and clinical researches on Neur-tinuous growth of axons from the olfactory epithelium into the CNS throughout the lifetime of the individual. orestoratology (3, 6, 7, 28, 42, 59, 80, 88, 93, 97) . Numerous studies on treating ALS with cells have been accom-
The olfactory system's capacity for axonal extension and target-specific synaptic interaction has been attrib-plished. Cell-based restorative treatment has become a new trend and rapidly increasing data worldwide have uted to the growth-promoting properties of OECs (40,80). Transplantation of these cells has been shown proven that it has a crucial therapeutic value in ALS (Tables 5 and 6) .
to have a neuroprotective effect, support axonal regeneration, remyelinate demyelinated axons, neuroplasticity, The community of clinical physicians, however, still believe that there are no methods that can control or neuromodulation or neural signal repair, neurogenesis, angiogenesis, anti-inflammatory response, reducing scar stabilize the progressive deterioration for ALS patients; therefore, self-comparison design was used in this study and cavity formation, and/or strong phagocytic activity (23, 49, 51, 56, 58, 60, 62, 68, 71, 72, 78, 79, 83, (85) (86) (87) 89, 91, 92 , as an effective tool to answer whether the treatment of multiple cell therapies have a positive role on deterio-94,96). A preclinical study by Martin and Liu (60) shows rated ALS, like the cell transplant research for corneal lesions, although the randomizing double blind control that adult olfactory bulb multipotent neural precursor cell (NPC) grafts provide temporary protection from study including placebo or sham-surgery is an important design to assess the effect in clinical medicine trials motor neuron degeneration, improve motor function, and extend survival in ALS mice. They delayed disease (38, 70) .
Herein, we provided the evidence of the feasibility onset to approximately 117 days, compared with control onset at approximately 90 days. The life span of NPC and efficacy of multiple OEC neurorestorotherapy in ALS patients and these new findings reinforced our pre-recipient mice was extended (approximately 170 days) compared with the life span of controls (approximately vious findings (9, 34, 35) . Our results clearly demonstrate that ALS patients recovered their neurological functions 140 days). In our lab, we found that OECs injected into the dorsal funiculus of thoracic spinal cord of and received benefit from multiple grafted OEC transplantation, which did not cause significant side effects.
SOD1G93A rats is feasible and safe; OECs prolong the survival of transgenic SOD1G93A rats compared with The patients appear to have a similar level of positive reaction after the first, second, third, fourth, or even fifth sham controls. The mechanism tests at 4 weeks after OEC transplantation reveal that the transplanted OECs cell therapy, although there were no statistical differences in several measures, which were most likely due not only can migrate at least 4.2 mm away from the injecting site, but also can protect motor neurons from to the obvious different sample size and homogeneity of 
